WakeMed

Managing HIV in the extreme: Viral load and drug monitoring in a patient with BMI > 60 on long‐acting cabotegravir/rilpivirine therapy

This case describes the use of long‐acting injectable (LA‐I) cabotegravir/rilpirivine (CAB/RPV) therapy in a morbidly obese person (body mass index [BMI] = 62 kg m −2 ) living with HIV without sustained viral load (VL) suppression after historic poor adherence to daily oral antir...